Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer

Clinical Breast Cancer

Volumn 7, Issue SUPPL. 1, 2007, Pages

  Coleman, Robert ^a,b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b Speaker's Bureau for Amgen and Novartis Oncology   (Switzerland)

Author keywords

Adjuvant therapy; Antiangiogenesis; Endocrine therapy; Nonskeletal recurrence; Osteoclasts

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; DACARBAZINE; DOXORUBICIN; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HUMAN; MULTIPLE CYCLE TREATMENT; ORTHOPEDIC SURGERY; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 34548211436     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.s.004     Document Type: Article

References (40)

1. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. Lyon: IARC Press; 2004. Available at: http://www-dep.iarc.fr. Accessed June 15, 2005.
2. Shibuya K, Mathers CD, Boschi-Pinto C, et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002; 2:37.
3. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2001. 2004. Accessed December 15, 2005.
4. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9(suppl 4):14-27.
5. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 2006; 20:2492-2506.
6. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005; 15:57-62.
7. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biopys Res Commun 2005; 328:679-687.
8. Roodman GD. Mechanisms of bone metastasis. N Eng J Med 2004; 350:1655-1664.
9. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001; 61:4432-4436.
10. Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
11. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006; 440:692-696.
12. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25:97-106.
13. Dunford JE, Thompson K, Coxon FE et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296:235-242.
14. Woodward J, Coleman RE, Holen I. Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion. Anticancer Drugs 2005; 16:11-19.
15. Woodward JK, Neville-Webbe HL, Coleman RE, et al. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 2005; 16:845-854.
16. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-1134.
17. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8:1080-1084.
18. Wood J, Bonjean K, Ruetz S, et al. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055-1061.
19. Neville-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002; 28:305-319.
20. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113:364-371.
21. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol 2001; 28:35-44.
22. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10:4559-4567.
23. Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen containing bisphosphonate suppresses melanoma growth and improves survival by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165:1865-1874.
24. Powles TJ, Paterson AE, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res Treat 2006; 8:R13. [Epub ahead of print]
25. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
26. Jaschke A, Bastert G, Solomayer EF, et al. Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up. Proc Am Soc Clin Oncol 2004; 22(14 suppl):9 (Abstract #529).
27. Saarto T, Vehmanen L, Virkkunen P, et al. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 2004; 43:650-656.
28. Kokufu I, Kohno N, Takao S, et al. Adjuvant pamidronate (PMT) therapy for the prevention of bone metastases in breast cancer (BC) patients with four or more positive nodes. Proc Am Soc Clin Oncol 2004; 22(14 suppl):9 (Abstract #530).
29. Jung J, Hwang G, Lee Y, et al. Pamidronate as adjuvant treatment for prevention of bone metastases in breast cancer. J Clin Oncol 2005; 23(16 suppl):99s (Abstract #888).
30. Kanis JA, Powles T, Paterson AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996; 19:663-667.
31. van Holten-Verzantvoort AT, Papapoulos SE. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer. Medicina Buenos Aire 1997; 57(suppl 1):109-113.
32. Data on file. Ciba-Geigy; Summit, NJ.
33. Van't Veer L, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome in breast cancer. Nature 2002; 415:530-536.
34. Wang Y, Klijn JG, Zhang Y, et al. Gene expression profiles to predict distant metastasis of lymph node negative primary breast cancer. Lancet 2005; 365:671-679.
35. Smid M, Wang Y, Klijn JG, et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006; 24:2261-2267.
36. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61-66.
37. Bellahcene A, Menard S, Bufalino R, et al. Expression of bone sialoprotein in human breast cancer is associated with poor survival. Int J Cancer 1996; 69:350-353.
38. Papotti M, Kalebic T, Volante M, et al Bone sialoprotein is predictive of bone metastases in resectable non-small cell lung cancer: a retrospective case-control study. J Clin Oncol 2006; 24:4818-4824.
39. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000; 6:521-528.
40. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12:1221-1228.